*0011368225
*008040507s2004    xx#           000 0 nob
*019  $bk
*08230$a615.7
*100  $aHofstad, Eivor$4ivr$_128804900
*245  $aBetaglukan avanserer til fase II
*300  $aS. 18-19 : port.
*520  $aIntervju med Glenn Gundersen
*650  $abetaglukaner$9nor$2norart$_133645500
*650  $aimmunstimulering$9nor$2norart$_129024300
*650  $alegemidler$9nor$2norart$_128631500
*700  $aGundersen, Glenn$4ive$_156428200
*773  $tLegemidler & samfunn$gÅrg. 25, nr 2 (2004)$x0803-6268$w(NO-LaBS)455583(tnr)
*999  $z400344636$anorart:400344636
^